A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
With the development of molecular biology and precise medical treatment, new challenges have been raised in the diagnosis and treatment of non-Hodgkin lymphoma (NHL) in children. In recent years, the criteria for clinical staging and efficacy evaluation of NHL in children have been updated. Studies in Germany and the United States have shown that pathological types of systemic anaplastic large cell lymphoma (ALCL) in children and adolescents, minimal disseminated disease (MDD) in peripheral blood or bone marrow and minimal residual disease (MRD) are significantly associated with prognosis, suggesting that these factors need to be combined in risk stratification of ALCL patients. Recent studies have also suggested that PET/CT is helpful in evaluating residual lesions in patients with lymphoma after chemotherapy. In order to keep pace with the times in the diagnosis, clinical staging, risk stratification, efficacy evaluation and treatment of NHL in children. We adjusted the original NHL-BFM-90/95 regimen, mainly in the aspects of clinical staging, efficacy evaluation, risk stratification and treatment regimen，etc.
Condition or disease
MRDMDDLymphoma, NonhodgkinAnaplastic LymphomaPediatric Cancer
To study the efficacy and safety of SCCCG-ALCL-2017 regimen in children with systemic ALK-positive anaplastic large cell lymphoma.
To explore the correlation between MDD or MRD in peripheral blood or bone marrow and the treat response and survival.
To explore the feasibility of risk stratification combined with adverse pathological types, dangerous organ invasion and MDD.
To investigate the effect of vinblastine maintenance chemotherapy on survival of patients with MRD-positive in peripheral blood after treatment.
Event-free survival (EFS) [ Time Frame: through study completion, maximal eight years ]
EFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease or relapse, treatment related death, death of any other cause or diagnosis of secondary malignancies
Secondary Outcome Measures :
Overall survival (OS) [ Time Frame: through study completion, maximal eight years ]
OS is defined as time from start of treatment/randomization up to death of any
Relapse-free survival (RFS) [ Time Frame: through study completion, maximal eight years ]
RFS is defined as time from start of treatment/randomization up to event or to date of last contact for patients without event. The following occurrences are defined as an event: non-response, progressive disease, or relapse.
Response rate (RR) [ Time Frame: on an average 3 weeks after finish of treatment ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
1 Year to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Systemic ALK-positive anaplastic large cell lymphoma patients # age at diagnosis < 18 years.
Age < 18 years old
Pathologically confirmed systemic ALK-positive anaplastic large cell lymphoma